All In Biotech

Drug Trial Radar · NCT06640933

A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants

A Phase 1, Randomized, Open-Label, Single-Dose, 6-Period Crossover Study to Evaluate the Pharmacokinetics of BIIB091 Formulations and the Effect of Food in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Oct 16, 2024

Primary completion

Feb 7, 2025

Study completion Feb 7, 2025

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study, researchers will learn how the body processes new tablet forms of BIIB091 when taken with and without food. One new form of BIIB091 is an "extended release" tablet, also known as "ER." This form helps release BIIB091 slowly and consistently, helping to keep steady drug levels in the body for longer. The other new form is a "gastro-retentive" tablet, also known as "GR." This form has a special coating that swells and allows BIIB091 to stay in the stomach longer. For both GR and ER tablets, there are also "slow" and "fast" forms that change how quickly BIIB091 is released into the body. But, eating food with these tablets may affect how much BIIB091 is in the body. The main objective of this study is to learn how 2 new forms of BIIB091, which are released into the body at different rates, are processed in the body. Researchers also want to learn how these new forms compare to the "immediate release" tablet, also known as "IR". This form delivers BIIB091 immediately into the body. The main question researchers want to answer in this study is: * How does the body process different tablet forms of BIIB091 with or without food? Researchers will also learn more about: * How the body processes the 2 new tablet forms of BIIB091 with food compared to the IR tablet form with food * How the body processes the ER tablet form of BIIB091 with food compared to without food * Any medical problems the participants have during the study * Any changes in the participants' overall health during the study This study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 22 days, after which eligible participants will check into their study research center. * Participants will be randomly assigned to 1 of 6 groups. In each group, the participants will take the below tablet forms, but in different orders: * Immediate-Release (IR) * Gastro-Retentive slow (GR-slow) * Gastro-Retentive fast (GR-fast) * Extended-Release slow (ER-slow) * Extended-Release fast (ER-fast) * ER-slow, without food * Each period includes the participant taking a single dose of what they were assigned to on the first day. There will be 3 days of no dosing in each period. The participant will then move to the next tablet form assigned. This will continue until each participant has taken a single dose of each of the 6 tablet forms. * Participants will remain at their study research center for 25 days for the treatment periods. Afterwards, there will be follow-up visit 11 to 14 days after each participant's last dose. Each participant will be in the study for up to 57 days.

Conditions

  • Healthy Volunteer

Interventions

  • BIIB091Drug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  2. AUC from Time Zero to Infinity (AUCinf) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  3. Maximum Observed Concentration (Cmax) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  4. Time to Reach Cmax (Tmax) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  5. Elimination Half-Life (t½) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  6. Time of Last Measurable Concentration (Tlast) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  7. Concentration of BIIB091 at 12 hours Postdose (C12h)Time frame: At multiple timepoints postdose (up to 12 hours)
  8. Apparent Clearance (CL/F) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)
  9. Apparent Volume of Distribution During the Terminal Elimination (VZ/F) of BIIB091Time frame: Predose and at multiple timepoints postdose (up to Day 4)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • PPD Las Vegas Research Unit

    Las Vegas, Nevada

  • PPD Clinical Research Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.